2 Information about autologous anti-CD19-transduced CD3+ cells

2 Information about autologous anti-CD19-transduced CD3+ cells

Marketing authorisation indication

2.1 Autologous anti-CD19-transduced CD3+ cells (Tecartus, Kite) are indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma after 2 or more lines of systemic therapy including a Bruton's tyrosine kinase (BTK) inhibitor.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.

Price

2.3 The price was submitted as commercial in confidence. The company has a commercial arrangement. This makes treatment with autologous anti‑CD19‑transduced CD3+ cells available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)